![Aura Biosciences](https://gocience.com/logos/new/d6cde355a9d567b2db9ec7747505388cbd2b291de9b40c8c577512c2cbca83fc.jpg)
Aura Biosciences
Biotechnology, 85 Bolton St, Boston, Massachusetts, 02140, United States, 51-200 Employees
Phone Number: 61********
Who is AURA BIOSCIENCES
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At ...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 85 Bolton St, Boston, Massachusetts, 02140, United States
-
Date Founded: 2009
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from AURA BIOSCIENCES
Aura Biosciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aura Biosciences
Answer: Aura Biosciences's headquarters are located at 85 Bolton St, Boston, Massachusetts, 02140, United States
Answer: Aura Biosciences's phone number is 61********
Answer: Aura Biosciences's official website is https://aurabiosciences.com
Answer: Aura Biosciences's revenue is $10 Million to $25 Million
Answer: Aura Biosciences has 51-200 employees
Answer: Aura Biosciences is in Biotechnology
Answer: Aura Biosciences contact info: Phone number: 61******** Website: https://aurabiosciences.com
Answer: Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month